Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin

Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives. To determine the effects of omal...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Theranostics
Main Authors: Metz, Martin, Staubach, Petra, Bauer, Andrea, Brehler, Randolf, Gericke, Janine, Kangas, Michael, Ashton-Chess, Joanna, Jarvis, Philip, Georgiou, Panayiotis, Canvin, Janice, Hillenbrand, Rainer, Erpenbeck, Veit J., Maurer, Marcus
Formato: Artigo
Idioma:Inglês
Publicado: Ivyspring International Publisher 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5399592/
https://ncbi.nlm.nih.gov/pubmed/28435464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.18304
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares